6-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934


For the month of June, 2020.

Commission File Number: 001-39071

ADC Therapeutics SA
(Exact name of registrant as specified in its charter)

Biopole
Route de la Corniche 3B
1066 Epalinges
Switzerland
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file
annual reports under cover of Form 20-F or Form 40-F:

Form 20-F
?

Form 40-F


Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ?

Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ?





SIGNATURE
      Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized.


ADC Therapeutics SA
Date: June 5, 2020




By:
/s/ Dominique Graz

Name:
Dominique Graz

Title:
General Counsel


EXHIBIT INDEX

Exhibit No.
Description
, 2020,
99.1
Press release dated June 5, 2020



1

EX-1

ADC Therapeutics to Host Conference Call to Highlight
Loncastuximab Tesirine (Lonca) Clinical Trial Data Being
Presented at Virtual EHA Annual Congress

	Updated data from pivotal Phase 2

	Updated data from Phase 1/2 in combination with ibrutinib

Lausanne, Switzerland, June 5, 2020
ADC Therapeutics SA
(NYSE:ADCT), a late clinical-stage oncology-focused
biotechnology company pioneering the development and
commercialization of highly potent and targeted antibody drug
conjugates for patients suffering from hematological
malignancies and solid tumors, announced today that it will
host a live conference call and webcast on Friday, June 12,
2020 at 8:30 AM EDT to highlight updated interim data from the
pivotal Phase 2 trial of Lonca in patients with relapsed or
refactory diffuse large B-cell lymphoma as well as interim
results of a Phase 1/2 trial highlighting the potential to
advance Lonca into earlier lines of therapy in combination
therapies that will be presented at the virtual 25th Congress
of the European Hematology Association (EHA25).

To access the call, please dial 833-526-8381 (domestic) or +41
225 805 976 (international) and request to join the ADC
Therapeutics conference call. A live webcast of the
presentation will be available on the Investors section of the
ADC Therapeutics website at www.adctherapeutics.com.

About ADC Therapeutics

ADC Therapeutics SA (NYSE:ADCT) is a late clinical-stage
oncology-focused biotechnology company pioneering the
development and commercialization of highly potent and
targeted antibody drug conjugates (ADCs) for patients
suffering from hematological malignancies and solid tumors.
The Company develops ADCs by applying its decades of
experience in this field and using next-generation
pyrrolobenzodiazepine (PBD) technology to which ADC
Therapeutics has proprietary rights for its targets. Strategic
target selection for PBD-based ADCs and substantial investment
in early clinical development have enabled ADC Therapeutics to
build a deep clinical and research pipeline of therapies for
the treatment of hematological and solid tumor cancers with
significant unmet need. The Company has multiple PBD-based
ADCs in ongoing clinical trials, ranging from first in human
to pivotal Phase 2 clinical trials, in the USA and Europe, and
numerous preclinical ADCs in development.

Loncastuximab tesirine (Lonca, formerly ADCT-402), the
Company's lead product candidate, has been evaluated in a 145-
patient pivotal Phase 2 clinical trial for the treatment of
relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
that showed a 45.5% interim overall response rate (ORR), which
exceeded the target primary endpoint. Camidanlumab tesirine
(Cami, formerly ADCT-301), the Company's second lead product
candidate, is being evaluated in a 100-patient pivotal Phase 2
clinical trial for the treatment of relapsed or refractory
Hodgkin lymphoma (HL) after having shown an 86.5% ORR in HL
patients in a Phase 1 clinical trial. The Company is also
evaluating Cami as a novel immuno-oncology approach for the
treatment of various advanced solid tumors.

ADC Therapeutics is based in Lausanne (Biopole), Switzerland
and has operations in London, the San Francisco Bay Area and
New Jersey.



Availability of Other Information About ADC Therapeutics

Investors and others should note that ADC
Therapeutics  communicates with its investors and the public
using its company website (https://adctherapeutics.com/),
including but not limited to investor presentations,
scientific presentations, Securities and Exchange Commission
filings, press releases, public conference calls and webcasts.
The information that ADC Therapeutics posts on these channels
and websites could be deemed to be material information. As a
result, ADC Therapeutics encourages investors, the media and
others interested in ADC Therapeutics to review the
information that it posts on these channels, including ADC
Therapeutics' investor relations website, on a regular basis.
This list of channels may be updated from time to time on ADC
Therapeutics' investor relations website and may include other
channels than the ones described above. The contents of ADC
Therapeutics' website or these channels, or any other website
that may be accessed from its website or these channels, shall
not be deemed incorporated by reference in any filing under
the Securities Act of 1933, as amended.

CONTACTS
Investors
Amanda Hamilton
ADC Therapeutics
amanda.hamilton@adctherapeutics.com
+1 917-288-7023

EU Media
Alexandre Muller
Dynamics Group
amu@dynamicsgroup.ch
+41 (0) 43 268 3231

USA Media
Annie Starr
6 Degrees
astarr@6degreespr.com
+1 973-415-8838